ArticleCirculation. Heart failure2016
Dying With a Left Ventricular Assist Device as Destination Therapy.
Article in Circulation. Heart failure, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- [Palliative care in patients with left ventricular assist devices: systematic review].Der Anaesthesist · 2021Pooled it
- Article
- Implantation of a Continuous-Flow Left Ventricular Assist Device During Cardiopulmonary Bypass Is Associated with a Significant and Transient Acute Thromboinflammatory Response.International journal of molecular sciences · 2026Article
- Everyone deserves a second chance: The importance of second opinions for left ventricular assist device candidacy.JHLT open · 2026Article
- Perioperative management and outcomes of hip and knee arthroplasty among heartmate 3 left ventricular assist device recipients.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2026Article
- From Fiber Architecture to Functional Attachment: A Clinically Relevant, Mechanically Tunable Cardiac Patch.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Review
- Left Ventricular Assist Device Destination Therapy: A Journey to Home and Beyond.JACC. Case reports · 2025Article
- Interprofessional Clinician Perspectives on LVAD Deactivation Compared to Dialysis Discontinuation: A Cross-Sectional Study Using Vignettes.JACC. Advances · 2025Article
- Impact of cardiac patch alignment on restoring post-infarct ventricular function.Biomechanics and modeling in mechanobiology · 2024Article
- Multicenter exploration of specialist palliative care in patients with left ventricular assist devices - a retrospective study.BMC palliative care · 2024Article
- Post-infarct evolution of ventricular and myocardial function.Biomechanics and modeling in mechanobiology · 2023Article
- End-of-Life Issues in Patients With Left Ventricular Assist Devices.Texas Heart Institute journal · 2023Article
- End-of-Life Care for End-stage Heart Failure Patients.Korean circulation journal · 2022Review
- Time Spent Engaging in Health Care Among Patients With Left Ventricular Assist Devices.JACC. Heart failure · 2022Article
- Ethical and Legal Concerns Associated With Withdrawing Mechanical Circulatory Support: A U.S. Perspective.Frontiers in cardiovascular medicine · 2022Review
- Inpatient Specialist Palliative Care in Patients With Left Ventricular Assist Devices (LVAD): A Retrospective Case Series.Frontiers in cardiovascular medicine · 2022Article
- HFA of the ESC position paper on the management of LVAD-supported patients for the non-LVAD specialist healthcare provider Part 3: at the hospital and discharge.ESC heart failure · 2021Article
- Perceptions of Bereaved Caregivers and Clinicians About End-of-Life Care for Patients With Destination Therapy Left Ventricular Assist Devices.Journal of the American Heart Association · 2021Article
- Palliative Care in Acute Heart Failure.Current heart failure reports · 2020Review
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
backgroundDespite the ability of left ventricular assist device as destination therapy (DT-LVAD) to prolong survival for many patients with advanced heart failure, little is known about the eventual end-of-life care that patients with DT-LVAD receive. METHODS AND
resultsAll patients undergoing DT-LVAD at the Mayo Clinic in Rochester, Minnesota, from January 1, 2007, to September 30, 2014, who subsequently died before July 1, 2015, were included. Information about end-of-life care was obtained from documentation in the electronic medical record. Of 89 patients who died with a DT-LVAD, the median (25th-75th percentile) time from left ventricular assist device implantation to death was 14 (4-31) months. The most common causes of death were multiorgan failure (26%), hemorrhagic stroke (24%), and progressive heart failure (21%). Nearly half (46%) of the patients saw palliative care within 1 month before death; however, only 13 (15%) patients enrolled in hospice a median 11 (range 1-315) days before death. Most patients (78%) died in the hospital, of which 88% died in the intensive care unit. In total, 49 patients had their left ventricular assist device deactivated before death, with all but 3 undergoing deactivation in the hospital. Most patients died within an hour of left ventricular assist device deactivation and all within 26 hours.
conclusionsIn contrast to the general heart failure population, most patients with DT-LVAD die in the hospital and few use hospice. Further work is needed to understand these differences and to determine whether patients with DT-LVAD are receiving optimal end-of-life care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.